医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Research and Markets: Lifecycle Management Strategies: Pharma-Payer Deals – Creative agreements are used at different stages of the brand lifecycle to maximize sales

2012年09月26日 AM02:12
このエントリーをはてなブックマークに追加


 

DUBLIN

Research and Markets (http://www.researchandmarkets.com/research/26rzgm/lifecycle) has announced the addition of the “Lifecycle Management Strategies: Pharma-Payer Deals – Creative agreements are used at different stages of the brand lifecycle to maximize sales” report to their offering.

With increasing cost-containment measures, payers have emerged as the key decision-making group, as proving the economic and clinical value of a drug is of central importance in achieving commercial success. As a result, pharma-payer deals have been used not only for launch products but also for mature brands in order to drive market share in the face of branded and generic competition alike.Analysis of success drivers and resistors of pharma-payer deals as a lifecycle management strategy. Discussion of how pharma-payer deals can satisfy key stakeholder needs.

Case study of recent successful and unsuccessful pharma-payer deals. Risk-sharing agreements are based on a “guaranteed” outcome resulting from the treatment, be that based on financial or outcome/performance criteria. If the outcome is achieved the payer will pay; if not, the pharmaceutical company refunds the payer for the cost of the drug. Risk-sharing agreements have the potential to reconcile the needs of different stakeholders: pharma companies secure market entry, the payer is financially protected from patients who fail to respond to drug treatment, and patients gain access to innovative therapies.

While straightforward discount and rebate deals are usually used to maintain sales later in the lifecycle when the drug in question is facing greater competition, recently, creative risk-sharing deals have also been used for mature brands in order to drive market share in the face of branded and generic competition alike. How can pharma-payer deals drive or maintain franchise sales? How can pharma-payer deals be used at different stages of a brand’s lifecycle? In which markets are pharma-payer deals commonly used?

Key Topics Covered:

– EXECUTIVE SUMMARY

– PHARMA-PAYER DEALS OVERVIEW

– PHARMA-PAYER DEALS CASE STUDIES

– BIBLIOGRAPHY

– APPENDIX

– TABLES

– FIGURES

Companies Mentioned

– Hutchison 3G UK Limited,

– Janssen Pharmaceuticals, Inc.

For more information visit http://www.researchandmarkets.com/research/26rzgm/lifecycle

CONTACT

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S.
Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • PHC株式会社:医薬品や試料の冷凍・冷蔵保存のさらなる安定化および、省エネルギー化と地球環境保護を追求したノンフロン薬用冷蔵ショーケース・薬用保冷庫を発売
  • 阿普塔宣布与威海恒煜医疗器材有限公司达成协议,在中国新增注射剂给药系统用弹性体和塑料组件的产能
  • Aptar Enters into Agreement with Weihai Hengyu Medical Products to Add Elastomeric and Plastic Component Manufacturing Capabilities in China for Injectable Drug Delivery
  • Japan’s Kewpie Corporation, Pioneer of the Hyaluronic Acid Revolution, Has Just Revealed Its Mechanism
  • FDA Clears Promega OncoMate™ MSI Dx Analysis System